









Markets
/
Stocks
/
nasdaq-ptix
/

Protagenic Therapeutics Inc

PTIX

0.740USD

0.0000.00%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

1.43MMarket Cap

43.10P/E TTM



Protagenic Therapeutics Inc

0.740

0.0000.00%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Protagenic Therapeutics Inc

Currency: USD Updated: 2026-01-02

Key Insights

Protagenic Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 216 out of 403 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Protagenic Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

216 / 403

Overall Ranking

479 / 4550

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Protagenic Therapeutics Inc Highlights

StrengthsRisks

Protagenic Therapeutics, Inc. is a neuroactive biopharmaceutical company. The Company has approximately six drug candidates targeting stress-related and CNS disorders, including treatments for obesity and metabolic disorders. The Company's pipeline includes PT-00114 in Phase I/IIa and five preclinical assets including PHYX-001, cannabinoid-based compounds, and modified stilbenoid assets. The PHYX-001 is a potassium channel modulator with a mechanism similar to XEN1101 and BHV-7000. The Company's cannabinoid assets include multiple cannabinoid-based compounds with composition-of-matter IP; potential in CNS, cardiometabolic, and other indications. The Company's cannabinoid assets also include a molecule with potential in the obesity, metabolic dysfunction sector, where the GLP-1 agonists have become medications. Its modified stilbenoid assets include modified stilbenoid compounds with composition-of-matter IP and anticonvulsant activity in preclinical models.

Overvalued

The company’s latest PE is 0.80, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 117.56K shares, decreasing 38.74% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-01-02

The current financial score of Protagenic Therapeutics Inc is 6.98, ranking 181 out of 403 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

0.00

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.10

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Protagenic Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-01-02

The current valuation score of Protagenic Therapeutics Inc is 6.29, ranking 309 out of 403 in the Biotechnology & Medical Research industry. Its current P/E ratio is 0.80, which is 12118.42% below the recent high of 97.85 and 2533.09% above the recent low of -19.48.

Score

Industry at a Glance

Previous score

0.00

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 216/403

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-01-02

No earnings forecast score is currently available for Protagenic Therapeutics Inc. The Biotechnology & Medical Research industry's average is 8.03.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-01-02

The current price momentum score of Protagenic Therapeutics Inc is 5.05, ranking 343 out of 403 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.49 and the support level at 0.35, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(5)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.015

Sell

RSI(14)

25.300

Sell

STOCH(KDJ)(9,3,3)

28.475

Sell

ATR(14)

0.172

High Vlolatility

CCI(14)

-203.437

Oversold

Williams %R

96.099

Oversold

TRIX(12,20)

-1.981

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.243

Sell

MA10

1.232

Sell

MA20

1.415

Sell

MA50

1.924

Sell

MA100

2.678

Sell

MA200

3.159

Sell

Institutional Confidence

Currency: USD Updated: 2026-01-02

The latest institutional shareholding proportion is 6.43%, representing a quarter-over-quarter increase of 41.20%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

0.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Armen (Garo H.)

52.75K

DRW Securities, LLC

36.21K

Connective Capital Management, LLC

28.60K

FNY Investment Advisers LLC

17.50K

Armistice Capital LLC

17.14K

Morgan Stanley Smith Barney LLC

15.00K

Barrage (Khalil Z)

10.78K

Arrow (Alexander K)

3.27K

Lovejoy (David A)

2.66K

Risk Assessment

Currency: USD Updated: 2026-01-02

No risk assessment score is currently available for Protagenic Therapeutics Inc. The Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 1.11. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.